oxford bio limited

BOARD OF DIRECTORS
OFFICES & LABS
INTERNAL PROGRAMS
PARTNERED PROGRAMS
PARTNERSHIPS
IMMUNE CHECKPOINT TARGETS
IO ANTIBODY ENGINEERING
OGAP DISCOVERY PLATFORM
PUBLICATIONS
PRESS RELEASES
OBT in the News

Harnessing immune cells to cure cancer

LentiVector ® platform

Press releases

Media contact details

Contact form

AAV platform

We work across key viral vector delivery systems including adeno-associated virus (AAV) to provide innovative solutions to cell and gene therapy biotechnology and biopharma companies.

We have built a sector leading lentiviral delivery system, LentiVector ® platform which is already used in commercially available treatments.

Discover Oxford Biomedica - a leading gene and cell therapy with over 25 years of experience.

Get in touch

Dr frank mathias to join oxford biomedica as new ceo on 27 march 2023, board change, oxford biomedica to present at 41st annual j.p morgan healthcare conference, oxford biomedica solutions forms new partnerships with three biotechnology companies.

More press releases

Our viral vector platform is enabling our customers to bring next generation treatments for serious diseases to market.

OXB is an innovative leading viral vector specialist – Lenti, AAV, Adeno and beyond - focused on delivering life changing therapies to patients.

Latest annual report

Go to downloads

Investors Go

Pipeline Go

Cookies on Companies House services

We use some essential cookies to make our services work.

We'd also like to use analytics cookies so we can understand how you use our services and to make improvements.

You've accepted analytics cookies. You can change your cookie settings at any time.

You've rejected analytics cookies. You can change your cookie settings at any time.

We use cookies to make our services work and collect analytics information. To accept or reject analytics cookies, turn on JavaScript in your browser settings and reload this page.

Please press ENTER to search

OXFORD BIO LIMITED

Company number 12661410

Next accounts made up to 30 June 2022 due by 31 March 2023

Last accounts made up to 30 June 2021

Confirmation statement

Next statement date 10 June 2023 due by 24 June 2023

Last statement dated 10 June 2022

Nature of business (SIC)

64304 - Activities of open-ended investment companies

Oxford Biosciences

Safety assessment, analysis, research & testing.

We offer the most comprehensive and affordable Cosmetic Product Safety Reports available with the fastest turnaround time in the industry, for clients worldwide. We also offer in-house Microbial Challenge Testing, and the most affordable UK, USA, and EU Responsible Person services worldwide.

Cosmetic Product Safety Reports

Uk & eu rp services.

Do you need Responsible Person services? We are global! We offer the most affordable UK, USA, and EU-based Responsible Person services with the fastest turnaround time in the industry. Click here for more information.

We produce high-value chemicals using patented enzyme technology

Our first product is natural nootkatone, the flavour and scent of grapefruit.

Our first products will be flavours and fragrances.

Our products

Find out more about our extensive library of patented cytochrome P450 enzymes.

The technology

Find out more about Oxford Biotrans and the people behind the business.

Latest news

Cyclic amine activation: nature synthesis article.

Please see the article out of our academic founder Prof. Luet Wong’s lab, for some exciting examples of cyclic amine CH activation by P450BM3 variants

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Read the video transcript

The BioEscalator

The BioEscalator, Oxford University's Biotech incubator, provides lab space and entrepreneurial support for high growth startups.

Oxford’s Old Road Campus is home to many of the University’s world-class institutes and departments, with 8500 staff and students tackling the full range of medical health challenges across the world. The BioEscalator builds on this success by nurturing early-stage biotech companies through to sustainability, by facilitating collaboration with NHS and academics, to build a community of entrepreneurial medical scientists and innovators.

Our focus is on getting more discoveries out of the lab and into patient care by providing fully equipped shared facilities allowing your company to start innovating from the moment you move in.

Latest Updates

Pictured left to right: Peter Jianrui Liu, CEO; Brad Wilson, Chairman; Andreas Halner, President and COO, Oxford Cancer Analytics

Oxford Cancer Analytics raises $3.7M led by Eka Ventures to revolutionise liquid biopsy and early cancer detection

10 January 2023

Oxford Cancer Analytics is pioneering a new generation of blood-based liquid biopsy tests for early cancer detection. It has announced the completion of an additional seed financing round, led by Eka Ventures, with participation from LifeArc, MegaRobo Technologies, Oxford Technology Management, and value-add individual investors. The Oxford and Toronto-based company has raised $5.5M to date. It will invest in expanding its first-in-class international studies and developing products for the deadliest cancers that can benefit most from liquid biopsy early detection.

Pictured: Dr Zhu Liang, Proteomics Scientist, with Dr Junetha Syed Jabarulla, OXcan Chief Scientific Officer

Oxford Cancer Analytics part of Oxford team that aims to detect lung cancer early via a simple blood test

16 December 2022

A team of Oxford scientists and clinicians has launched a study to detect the early stages of lung cancer using a blood test and machine learning. The team from Oxford University Hospitals (OUH) NHS Foundation Trust, the Oxford Radcliffe Biobank and the local spin-out company Oxford Cancer Analytics (OXcan) will recruit 200 participants to identify cancer biomarkers - molecules such as proteins found in blood that are a sign of lung cancer. Oxford Cancer analytics joined the BioEscalator community in June 2022.

Alethiomics and Infinitopes shortlisted in the New Startup of the Year category for the Cancer Research Horizons Innovation & Entrepreneurship Awards 2022

5 December 2022

Alethiomics is uncovering new biology to discover and develop life-changing treatments for patients with blood cancer, and Infinitopes is identifying hidden tumour targets, enabling the creation of high-efficiency vaccines.

Upcoming Events

Optimise your lab operations and improve lab sustainability

Thursday, 09 March 2023, 12pm to 1.30pm

A 30-minute seminar followed by a pizza lunch on the topic of lab sustainability. Be efficient. Be sustainable.

OBN BioTuesday: The importance of getting your company story right from the start

Tuesday, 14 March 2023, 6pm to 9pm

During this BioTuesday event, OBN will gather thought leaders from all corners of the life sciences industry to provide their views, practical know-how, experience, and guidance on the importance of getting your company story right from the start.

An image of different laboratory equipment such as beakers, test tubes and microscopes.

BioEscalator Mini Supplier Show

Tuesday, 21 March 2023, 10am to 3pm

Attending companies: Tebubio, Cryologyx, and Ichor Bio.

BioEscalator Bulletin no.6

Our Location

BioEscalator Innovation Building, University of Oxford, Old Road Campus, Roosevelt Drive, Oxford, OX3 7FZ

Photograph of the BioEscalator building and adjoining carpark, taken from the top of the Kennedy building

PSE Announcement

Due to the prodigious response to our press release regarding the Prostate Screening EpiSwitch® (PSE), we wanted to give everyone a quick update. Currently, the PSE is not commercially available, and no clinical trials are underway. We are working hard to bring this important test into the clinical lab for routine diagnostic testing. For more information regarding the PSE, please check out our press release and published article in Cancers. Thank you for being so supportive, and please check our website for future updates on this subject.

Oxford Biodynamics PLC

Commercializing episwitch ® 3d gene regulation for precision medicine.

Oxford Biodynamics' portfolio of clinical smart tests based on EpiSwitch® technology aims to help people face the most challenging health decisions with confidence and tackle the rising costs of healthcare.

A leap forward in treating cancer

A first-of-its-kind blood test to provide guidance on navigating the toughest challenges associated with use of an essential, widely-used class of cancer therapies: Immune Checkpoint Inhibitors.

Now every patient can benefit from the world’s first test to assess the probability of therapeutic success of checkpoint inhibitor therapy with high accuracy.

Vast, previously untapped data critical for health unlocked by the EpiSwitch platform

Enabling 3d genomics for precision medicine at scale.

The EpiSwitch platform is uniquely capable of reproducibly translating 3D genome regulation for clinical application.

In The News

To view and search our latest featured news, visit our in the news page.

Breaking the Silence

Quin Wills on ending liver disease as a silent killer.

At Ochre Bio, we’re developing therapies for the biggest liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. We're obsessive about...

Deep phenotyping livers at scale…, and designing precision rna therapies to reprogram them…, to regenerate human livers outside the body., chronic liver disease is the only top ten global killer on the rise, "liver disease is the third leading cause of premature death." uk health security agency, july 2021.

Jack O’Meara on how improving outcomes for liver transplant patients is a first step towards treating chronic liver disease

Built on decades of leading genomics and drug development experience, Ochre’s scientific teams are committed to making healthy livers available for patients everywhere.

We named Ochre Bio in honour of Nobel laureate, Sydney Brenner, for his remarkable scientific creativity. He passed away in 2019, the year Ochre was founded. We are a team who live by Clarke’s, Murphy’s, and Wheaton’s laws.

Owen Reilly

Sachin patil, michal matuszewski, esther arnaiz gonzalez, christine becker, thomas ormsby, raphael castellan, anthony beucher, alice preston, cheng-yuan yang, emmanuelle bitoun, ines mateus, jacinta tsao, kenny moore, fleur palmer-paquis, duygu yilmaz, robert mart, calum irwin, nick taylor, amita gupta, carlo ceresa, nina owen-simon, robert cosenza, rory cunningham, valentina greto, ashley hoffland, fabio sanna, francesca flintoft-burt, jack castle, jack o’ meara, lisa avenell, paul foster, shaysha rastogi, stephanie barnett-dean.

Reseach Associate

People & Culture Manager

Director, Preclinical Development

News & Announcements

Oxford biotech raises funds to make RNA treatments for liver disease

October 10, 2022

A liver disease upstart with some global connections and a new R&D strategy reaps a $30M launch round

RNA therapies startup Ochre Bio lands $30M to take on chronic liver disease

Ochre ideas, think you’d like to join our team, work at ochre, subscribe for updates.

Join our Mailing List

This website uses cookies to ensure you get the best experience on our website. view our policy here..

IMAGES

Oxford Hub Launch
About Us
The science behind the brand design for Oxford Biotrans, Milton Park, Oxford
Oxford Biomedica's revenues up, losses down
UK-based bio-engineering firm Oxford Genetics raises £7.5 million
Oxford-BioMedica4

VIDEO

TEDxKent

COMMENTS

Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) is a clinical stage oncology company focussed only on first-in-class immune therapies, with special emphasis on improving
OxfordBiomedica |
Discover Oxford Biomedica - a leading gene and cell therapy with over 25 years of ... Solutions forms new partnerships with three biotechnology companies.
OXFORD BIO LIMITED overview
OXFORD BIO LIMITED - Free company information from Companies House including registered office address, filing history, accounts, annual return, officers
Oxford Biosciences
Oxford Biosciences. Safety Assessment, Analysis, Research & Testing. We offer the most comprehensive and affordable Cosmetic Product Safety Reports
Oxford BioPharma
Welcome to Oxford BioPharma. Oxford BioPharma was established in April 2005 and is a science company providing consultancy services to the biotechnology
Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) is a clinical stage oncology company based in Oxford, UK; San Jose, CA and Morristown, NJ, USA, with a pipeline
Welcome
The BioEscalator, Oxford University's Biotech incubator, provides lab space and ... of getting your company story right from the start' | OBN (UK) Ltd‌.
Oxford Biodynamics PLC (OBD)
Oxford Biodynamics' portfolio of clinical smart tests based on EpiSwitch® technology aims to help people face the most challenging health decisions with
Ochre Bio
Oxford biotech raises funds to make RNA treatments for liver disease · A liver disease upstart with some global connections and a new R&D strategy reaps a $30M